PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3658115-2	1987	The maximal inhibition of ChE (78%) in plasma at 2 min correlated with the largest concentration of physostigmine (124 ng/ml).	Physostigmine	100-113	butyrylcholinesterase	Canis lupus familiaris	26-29	
7645197-2	1995	The anticholinesterase compound physostigmine was administered at various steady-state intravenous infusion rates based on pharmacokinetic estimates of plasma and red blood cell cholinesterase inhibition.	Physostigmine	32-45	butyrylcholinesterase	Canis lupus familiaris	8-22	
3666046-3	1987	Treatment of animals with the cholinesterase inhibitor, physostigmine, markedly inhibited the renal vasodilation produced by ibopamine, but had no effect on the renal vasodilator response of epinine.	Physostigmine	56-69	butyrylcholinesterase	Canis lupus familiaris	30-44	
3658115-3	1987	The concentration of physostigmine decreased by 88% to 16 ng/ml at 45 min when the activity of ChE was still 59% inhibited.	Physostigmine	21-34	butyrylcholinesterase	Canis lupus familiaris	95-98	
3785584-17	1986	This study suggests that intraventricular administration of physostigmine, a reversible inhibitor of cholinesterase (ChE), may offer distinct advantages over intravenous administration.	Physostigmine	60-73	butyrylcholinesterase	Canis lupus familiaris	101-115	
3785584-17	1986	This study suggests that intraventricular administration of physostigmine, a reversible inhibitor of cholinesterase (ChE), may offer distinct advantages over intravenous administration.	Physostigmine	60-73	butyrylcholinesterase	Canis lupus familiaris	117-120